Document Detail


Cardiac saphenous vein bypass graft disease.
MedLine Citation:
PMID:  15478036     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Coronary artery bypass grafting is an effective treatment for myocardial ischaemia and is particularly important in patients with multivessel disease and diabetes. However, up to 40% of saphenous vein grafts will occlude within 10 years of surgery. The predominant mechanisms for saphenous vein graft disease are thrombosis, intimal hyperplasia, and accelerated atherosclerosis. The pathology of these changes and the role of key factors such as nitric oxide, cellular proliferation, and the role of hypercholesterolemia and hypertriglyceridaemia, are reviewed. Saphenous vein graft disease is among the first cardiovascular conditions to show significant benefit from gene therapy and promises to show remarkable developments in the near future.
Authors:
G T Lau; H C Lowe; L Kritharides
Related Documents :
332366 - Morphologic observations in biologic conduits between aorta and coronary artery.
11565046 - The case for an in situ lesser saphenous vein bypass.
8903266 - Aortocoronary bypass with saphenous vein graft. seven-year follow-up. 1973.
8266266 - The continuing challenge of aneurysms of the popliteal artery.
22683616 - Aortic stenosis: a contemporary review.
3238666 - Thoraco-pleural actinomycosis presenting like diffuse pulmonary embolism.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Seminars in vascular medicine     Volume:  4     ISSN:  1528-9648     ISO Abbreviation:  Semin Vasc Med     Publication Date:  2004 May 
Date Detail:
Created Date:  2004-10-12     Completed Date:  2005-02-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100940307     Medline TA:  Semin Vasc Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  153-9     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Concord Repatriation General Hospital, Hospital Rd, Concord, NSW 2139, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cell Proliferation
Coronary Artery Bypass*
Diabetic Angiopathies / physiopathology
Graft Occlusion, Vascular / pathology,  physiopathology*
Humans
Hyperlipidemias / physiopathology
Nitric Oxide / physiology
Risk Factors
Saphenous Vein / pathology,  transplantation*
Vascular Endothelial Growth Factor A / therapeutic use
Chemical
Reg. No./Substance:
0/Vascular Endothelial Growth Factor A; 10102-43-9/Nitric Oxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hypothyroidism and cardiovascular disease: role of new risk factors and coagulation parameters.
Next Document:  Depressive disorders and the metabolic syndrome of insulin resistance.